Fig. 6: Quantitative imaging flow-cytometric detection of NCAD modalities triggered by paclitaxel, oxaliplatin, or cisplatin.

Simultaneously to the detection of CAD in Figs. 3 and 4, NCAD mechanisms were determined with the indicated concentrations of PCT, OXA, and CDDP and in the presence or absence of the indicated inhibitors after co-cultures of untreated (red) CMTMR-labeled cells (HCT116^WT cells (a, f, g, l, m), HCT116^+/+ cells (b, c), or MCF7 cells (d, e)) with untreated (green) CMFDA-labeled isogenic cells and after co-cultures of untreated (red) CMTMR-labeled cells (HCT116^WT cells (a, f, g, l, m), HCT116^+/+ cells (b, c), or MCF7 cells (d, e)) with PCT-, OXA-, or CDDP-treated (green) CMFDA-labeled isogenic cells. The detection of cell-in-cell structures (a–f, h–l) and target cell degradation (g, m) were performed as indicated in the legend of Fig. 5. Frequencies are shown (means ± SEM, n = 3). For b, c, asterisk (*) is used for the comparison of “HCT116^+/++PCT-treated HCT116^+/+” with “HCT116^+/++0 nM HCT116^+/+” for G(R), ampersand (&) is used for the comparison of “HCT116^+/++PCT-treated HCT116^+/+” with “HCT116^+/++0 nM HCT116^+/+” for R(G). For d, e, asterisk (*) is used for comparison of “MCF7+PCT-treated MCF7” with “MCF7+0 nM MCF7” cells for G(R), ampersand (&) is used for the comparison of “MCF7+PCT-treated MCF7” with “MCF7+0 nM MCF7” cells for R(G). For f, asterisk (*) is used for the comparison of “HCT116^WT+PCT-treated HCT116^WT” with “HCT116^WT+control (Co.) HCT116^WT” for G(R), ampersand (&) for the comparison of “HCT116^WT+PCT-treated HCT116^WT” with “HCT116^WT+control (Co.) HCT116^WT” for R(G), hash (#) for the comparison of inhibitor-treated cells with control cells for G(R), and dollar symbol ($) for the comparison of inhibitor-treated cells with respective control cells for R(G). For g, m, hash (#) is for the comparison of inhibitor-treated cells with respective control cells for target cell degradation. For h, i, asterisk (*) is used for the comparison of “HCT116^+/++OXA- or CDDP-treated HCT116^+/+” with “HCT116^+/++0 nM HCT116^+/+” cells for G(R), and ampersand (&) is used for the comparison of “HCT116^+/++OXA- or CDDP-treated HCT116^+/+” with “HCT116^+/++0 nM HCT116^+/+” for R(G). For j, k, asterisk (*) is used for the comparison of “MCF7+OXA- or CDDP-treated MCF7” with “MCF7+0 nM MCF7” for G(R) and ampersand (&) is used for the comparison of “MCF7+OXA- or CDDP-treated MCF7” with “MCF7+0 nM MCF7” for R(G). For l, asterisk (*) for the comparison of “HCT116^WT+OXA- or CDDP-treated HCT116^WT” cells with “HCT116 ^WT+control (Co.) HCT116 ^WT” cells for G(R), ampersand (&) for the comparison of “HCT116 ^WT+OXA- or CDDP-treated HCT116^WT” with “HCT116 ^WT+control (Co.) HCT116^WT” cells for R(G), hash (#) for the comparison of inhibitor-treated cells with control cells for G(R) and dollar symbol ($) for comparison of inhibitor-treated cells with respective control cells for R(G). *^{, #, $, &}p < 0.05; **^{, ##, $$, &&}p < 0.01; *** or ^&&&p < 0.001; and ****^{, $$$$, &&&&}p < 0.0001